Oncology Archive

A building with a stone facade displays a sign that reads
Amir Azadi, M.D.
A building with a stone facade displays a sign that reads
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
A building with a stone facade displays a sign that reads
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A building with a stone facade displays a sign that reads
A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
A building with a stone facade displays a sign that reads
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
A newly approved treatment is giving patients with advanced pancreatic cancer another option, and the physicians at HonorHealth Research Institute already have experience using it. The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a once-daily pill for certain patients with metastatic pancreatic cancer. In a large clinical trial, patients receiving the targeted therapy survived nearly twice as long, on average, versus those receiving standard chemotherapy. Months before FDA approval, HonorHealth Research Institute was among the first centers in the country selected to provide the treatment through an expanded access program. That early access allowed eligible patients to receive the investigational therapy while giving the Research Institute's pancreatic cancer team valuable experience with the treatment before it became more widely available. “Daraxonrasib is the first medication to demonstrate success targeting KRAS, a genetic mutation in more than 90% of pancreatic cancers, and its effectiveness opens the door for more targeted strategies against pancreatic and other cancers in the future,” said Erkut Borazanci, MD, director of oncology at HonorHealth Research Institute. Erkut Borazanci, M.D., M.S., Director of Oncology at HonorHealth Research Institute, pictured in a professional office portrait.
Early access to new pancreatic cancer treatment expands hope
A building with a stone facade displays a sign that reads
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
A building with a stone facade displays a sign that reads
PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
A building with a stone facade displays a sign that reads
A Phase 1 multicenter, open-label, study to evaluate the safety and pharmacokinetics of SHY-ONC6 in patients with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies
A man in a dark suit and purple tie stands indoors in front of a blurred background with large windows, as he prepares to present breakthrough research on synovial sarcoma immune-cell therapy.
Vaccine therapy offered at HonorHealth Research Institute shows potential for better treatment of advanced melanoma